Creso Pharma licensed to import its first medicinal cannabis product into Brazil

Australia’s Creso Pharma (ASX: CPH) has received approval to import its first medicinal cannabis product into Brazil. Creso and its marketing partner, SIN Solution, have received regulatory clearance from Brazilian health regulatory agency ANVISA for the importation of Creso’s medicinal cannabis product cannaQIX 50.

cannaQIX 50 has been developed for patients suffering from chronic pain and, in particular, chronic pain related to neuropathic diseases such as multiple sclerosis, Parkinson’s and cancer.

The commercialization of cannaQIX 50 in Brazil follows the product’s successful launch in New Zealand last year. Sales and marketing efforts in Brazil will be supported by Creso’s established partnership with SIN Solution, which will also engage in the support of patients’ access with regards to regulatory authorities and insurers.